Kerr Douglas 4

What Happened

• Kerr Douglas, Chief Medical Officer of Dyne Therapeutics (DYN), had 1,564 shares sold on May 13, 2026 for a total of $28,715. The reported weighted-average price was $18.36 per share (sales executed between $18.20 and $18.41).

Key Details

• Transaction date: 2026-05-13; Form filed: 2026-05-14.
• Transaction type: Sale (disposition) of 1,564 shares; total proceeds reported $28,715 (weighted avg $18.36).
• Price range: $18.20 to $18.41 (multiple transactions; issuer/staff may request breakdown).
• Reason: Automatic sale to satisfy tax withholding on RSUs that vested on Feb 12, 2026 (per footnote). The sale was pursuant to a binding RSU agreement and was not a discretionary trade by the insider.
• Holdings after transaction: Filing notes reported holdings include 148,313 unvested RSUs (as disclosed in the filing).

Context

• This was a routine, non-discretionary sale to cover tax withholding on vested restricted stock units, not an opportunistic open-market sell signal. The filing indicates the sale is consistent with a binding contract and the affirmative defense under Rule 10b5-1.